616 related articles for article (PubMed ID: 17514736)
1. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease is a prognostic marker for neuroblastoma with bone marrow infiltration.
Cai JY; Pan C; Tang YJ; Chen J; Ye QD; Zhou M; Xue H; Tang JY
Am J Clin Oncol; 2012 Jun; 35(3):275-8. PubMed ID: 21537148
[TBL] [Abstract][Full Text] [Related]
3. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
[TBL] [Abstract][Full Text] [Related]
4. Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction.
Tsang KS; Li CK; Tsoi WC; Leung Y; Shing MM; Chik KW; Lee V; Ng MH; Yuen P
Cancer; 2003 Jun; 97(11):2887-97. PubMed ID: 12767104
[TBL] [Abstract][Full Text] [Related]
5. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation.
Seriu T; Yokota S; Nakao M; Misawa S; Takaue Y; Koizumi S; Kawai S; Fujimoto T
Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394
[TBL] [Abstract][Full Text] [Related]
6. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
[TBL] [Abstract][Full Text] [Related]
7. Isolation and transplantation of highly purified autologous peripheral CD34(+) progenitor cells: purging efficacy, hematopoietic reconstitution and long-term outcome in children with high-risk neuroblastoma.
Handgretinger R; Lang P; Ihm K; Schumm M; Geiselhart A; Koscielniak E; Hero B; Klingebiel T; Niethammer D
Bone Marrow Transplant; 2002 May; 29(9):731-6. PubMed ID: 12040469
[TBL] [Abstract][Full Text] [Related]
8. Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden.
Feller N; Jansen-van der Weide MC; van der Pol MA; Westra GA; Ossenkoppele GJ; Schuurhuis GJ
Exp Hematol; 2005 Jan; 33(1):120-30. PubMed ID: 15661405
[TBL] [Abstract][Full Text] [Related]
9. Impact of minimal residual disease detection prior to autologous stem cell transplantation for post-transplant outcome in high risk neuroblastoma.
Bochennek K; Esser R; Lehrnbecher T; Glienke W; Wehner S; Erben S; Soerensen J; Schwabe D; Bader P; Klingebiel T; Koehl U
Klin Padiatr; 2012 Apr; 224(3):139-42. PubMed ID: 22377741
[TBL] [Abstract][Full Text] [Related]
10. Detection of residual neuroblastoma cells in bone marrow: comparison of flow cytometry with immunocytochemistry.
Swerts K; De Moerloose B; Dhooge C; Brichard B; Benoit Y; Laureys G; Philippé J
Cytometry B Clin Cytom; 2004 Sep; 61(1):9-19. PubMed ID: 15351977
[TBL] [Abstract][Full Text] [Related]
11. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
[TBL] [Abstract][Full Text] [Related]
12. A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis.
Gandhi M; Jestice H; Scott M; Bloxham D; Bass G; Craig J; Marcus R
Bone Marrow Transplant; 1999 Aug; 24(4):369-75. PubMed ID: 10467325
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric analysis of peripheral blood and bone marrow for tumor cells in patients with neuroblastoma.
Komada Y; Zhang XL; Zhou YW; Inaba H; Deguchi T; Azuma E; Sakurai M
Cancer; 1998 Feb; 82(3):591-9. PubMed ID: 9452279
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
[TBL] [Abstract][Full Text] [Related]
16. CNS recurrence following CD34+ peripheral blood stem cell transplantation in stage 4 neuroblastoma.
Choi HS; Koh SH; Park ES; Shin HY; Ahn HS
Pediatr Blood Cancer; 2005 Jul; 45(1):68-71. PubMed ID: 15770641
[TBL] [Abstract][Full Text] [Related]
17. CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients.
Kasow KA; Sims-Poston L; Eldridge P; Hale GA
Biol Blood Marrow Transplant; 2007 May; 13(5):608-14. PubMed ID: 17448921
[TBL] [Abstract][Full Text] [Related]
18. Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of post-transplant minimal residual disease using four- and six-color flow cytometry and allele-specific RQ-PCR.
Itälä M; Huhtinen AR; Juvonen V; Kairisto V; Pelliniemi TT; Penttilä TL; Rauhala A; Tienhaara A; Remes K
Eur J Haematol; 2008 Aug; 81(2):100-6. PubMed ID: 18410542
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma.
Stutterheim J; Zappeij-Kannegieter L; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
Eur J Cancer; 2011 May; 47(8):1193-202. PubMed ID: 21429738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
